<DOC>
	<DOCNO>NCT00286780</DOCNO>
	<brief_summary>This open-label Phase 2 study evaluate safety efficay AT-101 combination rituximab patient relapse refractory chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Phase 2 Safety Efficacy Study AT-101 Combination With Rituximab Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>Diagnosis CLL define NCIworking group Previous treatment standard systemic chemotherapy immunotherapy . Disease progression relapse treatment . Indication treatment define NCI Working Group Guidelines ( Cheson , 1996 ) ECOG performance status ≤ 2 Adequate liver renal bone marrow function Treatment CLL chemotherapy , monoclonal antibody radiotherapy within 60 day prior enter study . Acute toxicities prior therapy must resolve Grade ≤ 1 . Class 3 4 cardiac disease define New York Heart Association Functional Classification Severe debilitate pulmonary disease ( dyspnea rest , significant shortness breath , COPD ) Active secondary malignancy history malignancy within last five year Active symptomatic fungal , bacterial and/or viral infection include active HIV viral hepatitis ( A , B C ) . Patients contraindicate treatment rituximab Diagnosis prolymphocytic leukemia , hairy cell leukemia , leukemic phase nonHodgkin 's lymphoma , nonBCLL Bcell malignancy ; TCLL Tcell malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>AT101</keyword>
	<keyword>AT-101</keyword>
	<keyword>cancer</keyword>
	<keyword>lymphoctic</keyword>
	<keyword>lukemia</keyword>
	<keyword>Rituximab</keyword>
</DOC>